219
Views
22
CrossRef citations to date
0
Altmetric
Review

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin

, , , , &
Pages 989-1001 | Published online: 17 Sep 2013

Abstract

Type 2 diabetes mellitus is a complex and progressive disease that is showing an apparently unstoppable increase worldwide. Although there is general agreement on the first-line use of metformin in most patients with type 2 diabetes, the ideal drug sequence after metformin failure is an area of increasing uncertainty. New treatment strategies target pancreatic islet dysfunction, in particular gut-derived incretin hormones. Inhibition of the enzyme dipeptidyl peptidase-4 (DPP-4) slows degradation of endogenous glucagon-like peptide-1 (GLP-1) and thereby enhances and prolongs the action of the endogenous incretin hormones. The five available DPP-4 inhibitors, also known as ‘gliptins’ (sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin), are small molecules used orally with similar overall clinical efficacy and safety profiles in patients with type 2 diabetes. The main differences between the five gliptins on the market include: potency, target selectivity, oral bioavailability, long or short half-life, high or low binding to plasma proteins, metabolism, presence of active or inactive metabolites, excretion routes, dosage adjustment for renal and liver insufficiency, and potential drug–drug interactions. On average, treatment with gliptins is expected to produce a mean glycated hemoglobin (HbA1c) decrease of 0.5%–0.8%, with about 40% of diabetic subjects at target for the HbA1c goal <7%. There are very few studies comparing DPP-4 inhibitors. Alogliptin as monotherapy or added to metformin, pioglitazone, glibenclamide, voglibose, or insulin therapy significantly improves glycemic control compared with placebo in adult or elderly patients with inadequately controlled type 2 diabetes. In the EXAMINE trial, alogliptin is being compared with placebo on cardiovascular outcomes in approximately 5,400 patients with type 2 diabetes. In clinical studies, DPP-4 inhibitors were generally safe and well tolerated. However, there are limited data on their tolerability, due to their relatively recent marketing approval. Alogliptin will be used most when avoidance of hypoglycemic events is paramount, such as in patients with congestive heart failure, renal failure, and liver disease, and in the elderly.

Introduction

In 2011, there were 366 million people with diabetes worldwide, and this is expected to rise to 552 million by 2030, rendering previous estimates very conservative.Citation1 Excluding accidents, diabetes is the fifth cause of death for women and the fourth for men in the USA.Citation2 Tight glycemic control, to maintain a hemoglobin A1c (HbA1c) concentration of 7% or lower, is recommended for many nonpregnant adults with diabetes to minimize the risk of long-term vascular complications.Citation3 As a consequence, current diabetes guidelinesCitation4 suggest adjustment of therapy based on HbA1c level. However, there is little evidence about the relative effects of various antihyperglycemic therapies on clinical outcomes, with the possible exception of metformin, which appears moderately protective on cardiovascular (CV) outcomes.Citation5

Although there is general agreement on the first-line use of metformin in most patients with type 2 diabetes, the ideal drug sequence after metformin failure is an area of increasing uncertainty,Citation6 given the panoply of diabetes medications so far available for treatment of hyperglycemia. There are 45 rational and US Food and Drug Administration-permissible combinations that can be used in dual therapy.Citation7 A recent estimate claims 150 therapeutic options for triple therapy and 600 options for quadruple therapy, not including the different options within each class, for example, basal vs premixed insulin.Citation8

The failure to achieve glycemic goals in a large portion of this population is, in part, due to limitations in the current treatment options available to patients with type 2 diabetes. Many oral diabetes medications are associated with side effects that limit their use, including hypoglycemia (sulfonylureas, insulin, meglitinides), weight gain (sulfonylureas, thiazolidinediones, insulin), gastrointestinal side effects (metformin, exenatide, α-glucosidase inhibitors), and fluid retention (thiazolidinediones and insulin). Even if these medications are initially effective, glycemic control gradually worsens over time in most patients owing to a steady and progressive decline in pancreatic β-cell function. There is at present no robust evidence that a single therapeutic agent can address all pathogenetic factors associated with the progressive exhaustion of beta cells. As a corollary, most type 2 diabetic patients require more than one pharmacological option to achieve glycemic target. Ultimately, most patients will require insulin therapy.Citation9

Antihyperglycemic agents also have the potential to contribute to therapeutic inertia, defined as the failure of health care providers to initiate or intensify therapy when indicated,Citation10 via factors inherent to the drugs themselves, such as treatment-related adverse effects, perception of long-term safety profiles, and the complexity of the treatment regimen. Perhaps it is not by chance that the position statement from the American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) on the management of hyperglycemia in type 2 diabetes is subtitled ‘a patient-centered approach’.Citation4 This statement highlights the clinical judgment (a mixture of clinical experience, knowledge, and skill) of physicians together with the patients’ values and preferences. However, physician feeling and conviction about the willingness to reach the HbA1c target (now tailored on the patient) remain paramount to reduce unnecessary therapeutic inertia.Citation11

An improved understanding of the pathogenesis of type 2 diabetes, including postprandial control of glucose homeostasis, has led to the emergence of new treatment strategies that target pancreatic islet dysfunction, in particular those that target gut-derived incretin hormones.

The incretin system

More than 20 years ago, Gutniak et alCitation12 suggested that glucagon-like peptide-1 (GLP-1) might be a potential target in the treatment of type 2 diabetes, as they demonstrated that its intravenous infusion reduced the insulin requirement to meal ingestion in subjects with diabetes. At that time, it was already known that oral glucose ingestion elicited a greater insulin response than did intravenous glucose infusion, at the same level of attained glycemia.Citation13 Later, this was called the incretin effect, and attributed to an increased glucose-stimulated insulin secretion induced by the gut incretin hormones released after glucose ingestion.Citation14

The two incretin hormones with the greatest effect on glucose control are GLP-1 and glucose-dependent insulinotropic peptide (GIP). Both peptides are secreted within minutes of food consumption and act on pancreatic beta cells, through distinct receptors, to stimulate insulin secretion with dependency on blood glucose concentration; when glucose levels are normal, incretin-stimulated insulin secretion is suppressed.Citation15 GLP-1 is a product of the proglucagon gene and is secreted from the L cells located in the distal gut into the capillaries and then into the blood stream. Activation of the GLP-1 receptors (Gαs protein-coupled receptors) expressed on the pancreatic β-cells elevates cAMP levels, which in turn activates protein kinase A and Epac 1 and 2, resulting in a glucose-dependent increase of insulin secretion by the β-cell.Citation16 GLP-1 infusions have shown more promising results than those of GIP in lowering plasma glucose in diabetes. Other effects of GLP-1 include suppression of glucagon secretion, also exerted in a glucose-dependent manner, slowing of gastric emptying time, and promotion of satiety. The net effect of enhanced insulin secretion and suppressed glucagon secretion is decreased fasting and postprandial glucose levels. GLP-1 also increases β-cell mass through differentiation and proliferation of β-cells and inhibition of apoptosis, as shown in rodents.Citation17 Since all of these effects are of potential value in the treatment of type 2 diabetes, GLP-1 has intensively been explored as a pharmacological therapy for the disease.

The incretin effect is greatly reduced in patients with type 2 diabetes – this plays an important contributory role in the insulin insufficiency and chronic hyperglycemia characteristic of the disease.Citation18 The short half-life (1–2 minutes) of GLP-1 is a consequence of its rapid inactivation by the enzyme dipeptidyl peptidase-4 (DPP-4) that truncates the peptide by removal of the N-terminal dipeptide end. GLP-1 effects can be provided therapeutically by giving supplemental GLP-1 agonists, which are largely resistant to the action of DPP-4; the other approach is to inhibit the enzyme DPP-4, which slows degradation of endogenous GLP-1, and thereby enhances and prolongs the action of the endogenous incretin hormone.

DPP-4 inhibitors: pharmacology, mode of action, pharmacokinetics

DPP-4 (also known as lymphocyte cell surface protein CD26) is a membrane-spanning, cell-surface aminopeptidase ubiquitously expressed in many tissues, such as gut, lymphocyte, liver, kidney, lung, and endothelial cells.Citation17 DPP-4 enzyme is a member of the DPP family, which also includes the structurally related enzymes DPP-2, DPP-8, DPP-9, and fibroblast activation protein; DPP-4 has several substrates, such as gastrointestinal hormones, neuropeptidase, cytokines, and chemokines.Citation19

The five available DPP-4 inhibitors, also known as ‘gliptins’ (sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin), are small molecules used orally with similar overall clinical efficacy and safety profiles in patients with type 2 diabetes. Sitagliptin was the first gliptin licensed by the US Food and Drug Administration (FDA) in 2006 () and is now available worldwide;Citation20 vildagliptin and saxagliptin were approved in 2007 and 2009, respectively.Citation21,Citation22 More recent compounds are alogliptin (available only in Japan in 2010) and linagliptin (authorized by the FDA and EU in 2011).Citation23,Citation24 DPP-4 inhibitors may be used as monotherapy or in double or triple combination with other oral glucose-lowering agents, as metformin, thiazolidinediones, or sulfonylureas. The authorized combined therapies in EU are reported in . Sitagliptin, vildagliptin, and saxagliptin are currently available as single agents or in a fixed-dose combination with metformin.

Table 1 DPP-4 inhibitors-based medicines authorized through central procedure by the European Medicines Agency (EMA)

Table 2 The combinations between DPP-4 inhibitors and other oral glucose-lowering agents authorized by the European Medicines Agency (EMA)

DPP-4 inhibitors reduce plasma DPP-4 activity by 70%–90% in a sustained manner for 24 hours with an increase of GLP-1 levels (1.5- to 4-fold). They do not pass the blood–brain barrier, have no direct central effect on satiety, and in contrast with GLP-1 agonists (incretin mimetics), did not alter gastric emptying.Citation25 Although DPP-4 inhibitors have the same mode of action, they differ by some important pharmacokinetic and pharmacodynamic properties that may be clinically relevant in some patients.Citation19 The main differences between the five gliptins on the market include: potency, target selectivity, oral bioavailability, long or short half-life, high or low binding to plasma proteins, metabolism, presence of active or inactive metabolites, excretion routes, dosage adjustment for renal and liver insufficiency, and potential drug–drug interactions ().

Table 3 Main pharmacokinetic and pharmacodynamic properties of DPP-4 inhibitors available on the European market

Pharmacodynamic properties

Regarding potency, linagliptin, compared with sitagliptin, alogliptin, saxagliptin, and vildagliptin demonstrated the highest potency of DPP-4 inhibition (IC50 values of 1 nM, 19 nM, 24 nM, 50 nM, and 62 nM, respectively).Citation19,Citation26,Citation27 The duration of action of DPP-4 inhibitors with comparatively shorter half-lives may be strongly influenced by binding strength and reversibility with the receptor.Citation28 All gliptins exhibit a greater selectivity for DPP-4 enzyme, ranging from 30- to 40,000-fold superior to the other enzymes, ie, DPP-8 and DPP-9.Citation28,Citation29 However, because DPP-8 and DPP-9 are proteases responsible for T-cell activation which play an important role in immune function, the off-target inhibition of selective DPP-4 inhibitors is responsible for toxicity (immune dysfunction, impaired healing, and skin reactions).Citation29

Pharmacokinetic properties

After oral administration in humans, all DPP-4 inhibitors are well absorbed with oral bioavailability ranges from approximately 30% with linagliptin to 75%–87% for all others and are not significantly influenced by food intake.Citation30 Linagliptin has the longest half-life (120–184 hours), followed by alogliptin (12.4–21.4 hours), and sitagliptin (8–14 hours), whereas saxagliptin and vildagliptin have shorter half-lives (2.2–3.8 hours and 2–3 hours, respectively). Due to a sustained DPP-4 enzyme inhibition and a long half-life, sitagliptin, alogliptin, and linagliptin are generally prescribed once a day. Saxagliptin is also administrated once daily due to the presence of an active metabolite (5-hydroxy saxagliptin) which is half as potent as the parent compound. Due to the shorter half-life, vildagliptin needs twice-daily dosing.Citation31 The apparent volumes of distribution (Vd) among the gliptins range from 70 to 918 L.Citation25 Moreover, the distribution of DPP-4 inhibitors is strongly influenced by protein binding. All gliptins are not extensively bound to plasma proteins, except for linagliptin, which has the highest binding level to proteins.Citation32

DPP-4 inhibitor metabolism is widely variable. While sitagliptin does not appear to undergo extensive metabolism, both vildagliptin and saxagliptin are extensively metabolized in the liver. However, vildagliptin produces a large amount of inactive metabolites through several pathways (hydrolysis, glucuronidation, and oxidation) not mediated by the cytochrome P450 (CYP) system, while saxagliptin is mainly metabolized by the CYP3A4/5 isoforms to a major active metabolite, 5-hydroxy saxagliptin (which is 2-fold less potent than its parent molecule).Citation32Citation34 Both saxagliptin and its major metabolite are not inhibitors or inducers of various CYP isoforms.Citation32 Although the potential for drug interactions with saxagliptin and its metabolite is low, their pharmacokinetic profile may be influenced in co-administration with strong CYP3A4/5 inducers (such as rifampicin) or inhibitors (such as ketoconazole); in these cases, it is recommended to modify the dosage of saxagliptin.Citation34,Citation35 The pharmacokinetic profiles of the other DPP-4 inhibitors suggest a low risk of drug–drug interactions,Citation32 which is especially favorable in patients older than 65 years.Citation35

All DPP-4 inhibitors predominantly (75%–87%) undergo renal excretion, with 76%–87% of each dose eliminated as unchanged parent compound in the urine. In contrast, linagliptin is excreted mostly (~90%) unchanged in feces via biliary excretion,Citation19,Citation25 and therefore appears to be safe in diabetic patients suffering from renal complications.Citation29,Citation34 An appropriate dose reduction of the gliptins with predominantly renal excretion (sitagliptin, saxagliptin, and alogliptin, but not vildagliptin) is required in case of renal impairment.Citation25,Citation29,Citation32 In patients with mild to severe liver impairment, no dose adjustment seems necessary for linagliptin despite its liver excretion.Citation25

Efficacy studies

In a meta-analysis of randomized controlled trials (RCTs) through September 2010,Citation36 we assessed the effectiveness of different DPP-4 inhibitors to reach the recommended HbA1c target of <7% in people with type 2 diabetes. Of the 1,438 citations identified, we selected 43 studies, with 10,467 patients treated with a DPP-4 inhibitor. All studies were published between 2005 and 2010; all studies were of parallel groups, and most studies were of double- or triple-blind design. The duration of the studies ranged from 12–52 weeks, and most arms were of 24–26 weeks.

There were 14 RCTs testing vildagliptin, with 4,288 subjects. The direct random effect meta-analysis of RCTs showed that 37% of subjects achieved the HbA1c goal of <7% at the end of treatment, without differences between the four arms in which vildagliptin was added to metformin and the nine arms in which vildagliptin was used in monotherapy (). The mean decrease in HbA1c was 0.88%, body weight change was 0.165 kg, and the frequency of hypoglycemia was 1.4% ().

Figure 1 Proportion of patients with HbA1c <7%, and absolute decrease of HbA1c from baseline at endpoint in patients with type 2 diabetes on gliptins after failure of previous treatments.

Note: Basal HbA1c represents the mean baseline HbA1c level at randomization.
Figure 1 Proportion of patients with HbA1c <7%, and absolute decrease of HbA1c from baseline at endpoint in patients with type 2 diabetes on gliptins after failure of previous treatments.

Figure 2 Proportion of patients with hypoglycemia (%) and changes in weight (kg) in patients with type 2 diabetes on gliptins after failure of previous treatments.

Figure 2 Proportion of patients with hypoglycemia (%) and changes in weight (kg) in patients with type 2 diabetes on gliptins after failure of previous treatments.

There were 18 RCTs testing sitagliptin, with 3,646 subjects. The meta-analysis showed that 37% of subjects achieved the HbA1c goal of <7% at the end of treatment, without differences between the eight arms in which sitagliptin was added to metformin and the seven arms in which sitagliptin was used in monotherapy (). The mean decrease in HbA1c was 0.71%, body weight change was −0.254 kg, and the frequency of hypoglycemia was 3.1% ().

There were nine RCTs testing saxagliptin, with 1,608 subjects. The meta-analysis showed that 38% of subjects achieved the HbA1c goal of <7% at the end of treatment, without differences between the six arms in which saxagliptin was used at the 5 mg dose, and the three arms in which it was used at the 10 mg dose (). The mean decrease in HbA1c was 0.8%, body weight change was −0.20 kg, and the frequency of hypoglycemia was 3.4% ().

There are few studies comparing DPP-4 inhibitors. There are no head-to-head studies reported comparing sitagliptin and vildagliptin, nor have there been studies comparing alogliptin with these currently approved DPP-4 inhibitors. Caution must therefore be exercised in judging relative efficacy. There is one head-to-head study showing no difference in the effect of saxagliptin combined with metformin as compared with sitagliptin plus metformin.Citation37 The improvements in HbA1c seen with alogliptin seem to be in the same range as those seen with other DPP-4 inhibitors.Citation36

Focus on alogliptin

In the pivotal, 26-week, Phase III monotherapy trialCitation38 in drug-naïve type 2 diabetic patients inadequately controlled with diet and exercise, alogliptin treatment resulted in significantly greater improvements in glycemic control than placebo, in terms of changes from baseline in HbA1c and fasting glucose levels, and achievement of prespecified target levels of HbA1c (HbA1c <6.5% or 7%). Moreover, fewer alogliptin (12.5 and 25 mg/day groups) than placebo recipients required hyperglycemic rescue. There were no statistically or clinically meaningful changes in body weight in both alogliptin groups versus the placebo group. There were also significant (P < 0.006) improvements in total cholesterol levels in the alogliptin groups after 26 weeks of treatment, but no difference in HDL-cholesterol, LDL-cholesterol, or triglyceride levels.

Alogliptin plus metformin,Citation39 pioglitazone,Citation40 glibenclamide,Citation41 voglibose,Citation42 or insulinCitation43 therapy significantly improved glycemic control compared with placebo in adult patients with inadequately controlled type 2 diabetes. After 26 weeks, changes from baseline in HbA1c levels, which were apparent from week 4 onwards, were all significantly greater in the alogliptin 12.5 mg group (range −0.4% to −0.7%) and 25 mg group (range −0.5% to −0.8%) than in placebo recipients (range −0.2% to +0.01%). Consistent with these findings, significantly more patients in the alogliptin groups than in the placebo groups achieved HbA1c target levels (HbA1c <6.5% or <7.0%).

The efficacy of alogliptin in elderly patients with inadequately controlled diabetes has been evaluated in a pooled analysis.Citation44 The elderly people (aged ≥65 years; n = 455) were compared to younger people (aged <65 years; n = 1911). There were no statistically significant differences between the two age groups in terms of improvements in glycemic control (HbA1c or fasting blood glucose decrease from baseline), irrespective of whether patients had a baseline HbA1c level of ≤8% or >8%. In addition, 37% of younger patients achieved an HbA1c level of ≤7% at week 26 (both alogliptin doses). In elderly patients, this target HbA1c level was achieved by 45% of patients on both alogliptin doses. There were no significant differences between treatment groups or between younger and elderly patients in terms of body weight changes from baseline, or lipid parameters. shows the characteristics of the studiesCitation38Citation42,Citation45Citation51 hitherto published evaluating the efficacy and tolerability of alogliptin at different doses in type 2 diabetic patients not adequately controlled on previous treatments.

Table 4 Characteristics of the studies with alogliptin

The EXAMINE trial

As a result of concerns regarding the association of antidiabetic agents with adverse CV outcomes,Citation52 the FDA released a guidance in December 2008 titled, ‘Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes’.Citation53 This guidance outlines requirements for CV safety assessment before and after approval of all new antidiabetic therapies. Specifically, sponsors must rule out an upper 95% confidence interval (CI) of the hazard ratio (HR) of 1.8 before approval and 1.3 after approval. Alogliptin has been studied in 3,489 diabetic patients and 1,213 patients on placebo in seven 26-week studies and one 12-week study (Phase III studies). Compared with placebo, treatment with alogliptin was associated with a reduced risk (HR: 0.61, 95% CI: 0.24–1.56) of adjudicated major adverse CV events (MACE), defined as death from CV disease, nonfatal myocardial infarction, or nonfatal stroke.Citation54 However, the CV event rate was too low to rule out a concern in patients with higher baseline risk.

EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE (EXAMINE)Citation55 is a Phase III, multicenter, prospective, double-blind randomized trial in which alogliptin is being compared with placebo on CV outcomes in approximately 5,400 patients with type 2 diabetes and a well-defined acute coronary syndrome event (myocardial infarction or hospitalization with unstable angina). The primary objective of EXAMINE is to demonstrate the noninferiority of MACE on alogliptin versus placebo in the treatment of type 2 diabetes in a high-risk CV patient group. The study consists of a screening period of up to 2 weeks and a follow-up period of 4.75 years. The length of the study participation will vary but is estimated to be a median of 2 years of study drug treatment. The statistical plan for the trial uses a design that evaluates the HR of alogliptin to placebo first based on the primary CV composite end-point after accrual of 80–150 primary CV events and again when there are 550–650 primary CV events. Long-term CV safety of alogliptin is being established using an analytical approach that has both an interim and final assessment. In the first series of analyses, the upper boundary of a group-sequential 1-sided repeated CI for the HR must be ≤1.8 for registration in the USA. At the end of the study, the upper boundary of a subsequent group-sequential 1-sided repeated CI for the HR must be ≤1.3.

Safety and tolerability

In clinical studies, DPP-4 inhibitors were generally safe and well-tolerated.Citation56 However, there is limited data on their tolerability, in particular on onset of rare events, due to their relatively recent marketing approval. As a drug class, the DPP-4 inhibitors have become accepted in clinical practice due to their excellent tolerability profile, with a low risk of hypoglycemia, a neutral effect on body weight, and once-daily dosing.Citation57

In many clinical studies, the most common adverse events (AEs) with incretin therapy were gastrointestinal events, such as vomiting and diarrhea, which generally diminish over time or with a dose-escalation strategy.Citation28,Citation56 Nausea, which is the most common AE observed with GLP-1 receptor agonist therapy, is not frequently observed in treatment with DPP-4 inhibitors.Citation56 Moreover, both GLP-1 agonists and metformin were associated with a higher discontinuation rate than DPP-4 inhibitors, which is probably related to their higher incidence of gastrointestinal reactions (diarrhea, nausea, and vomiting).Citation58 So far, no characteristic pattern of adverse events has been associated with the DPP-4 inhibitors despite the large number of potential substrates for DPP-4.Citation17,Citation28 DPP-4 inhibitors are less associated with several specific AEs of traditional antidiabetic treatments.Citation26 The neutral effect on body weight of DPP-4 inhibitors can be useful in overweight or obese patients with type 2 diabetes, while the low risk of hypoglycemia may be an advantage in the elderly.Citation25 Hypoglycemic events are mainly observed when DPP-4 inhibitors are associated with sulfonylureas (in 20% of the patients treated in combination) than without sulfonylureas.Citation25,Citation28

In clinical trials, other AEs commonly correlated to DPP-4 inhibitors are of mild severity and include nasopharyngitis, headache, and urinary tract infections (UTIs).Citation59Citation61 Another meta-analysis failed to find differences in the incidence of nasopharyngitis, upper respiratory tract infections (URTIs), and UTIs between DPP-4 inhibitors and the other hypoglycemic drugs.Citation58 The biological plausibility of the risk associated with this class of drugs may be related to the important role DPP-4 plays in the immune system, being a T-cell co-stimulator.Citation26,Citation62 In post-marketing, new AEs have been reported, including hypersensitivity reactions (angioedema, skin toxicity such as Stevens–Johnson syndrome),Citation26,Citation63 and also increased rates of infections.Citation59 In a nested case–control study conducted using VigiBase, the World Health Organization’s Adverse Drug Reactions database, the spontaneous reporting of infections (primarily URTIs) was higher for patients using DPP-4 inhibitors (sitagliptin, vildagliptin, and saxagliptin) compared with users of other antidiabetic drugs (in particular metformin).Citation64 Regarding the newer gliptins (alogliptin and linagliptin), close postmarketing vigilance is required because of a limited exposure to these agents at this time.Citation31

Although a rare event, pancreatitis has been reported in sitagliptin- and exenatide-treated patients.Citation34 However, patients with type 2 diabetes have a near three-fold baseline risk of suffering from acute pancreatitis.Citation65 In particular, in 2006, the US FDA received 88 reports of acute pancreatitis in patients who received sitagliptin treatment (as monotherapy or in combination with metformin), including two cases of fatal hemorrhagic or necrotizing pancreatitis, and serious nonfatal cases.Citation66 Besides these reports, six patients with hemorrhagic or necrotizing pancreatitis treated with exenatide required hospitalization, and two of them died.Citation67 The attention on this concern is still strong. As emphasized on the FDA website,Citation68 a recent population-based, case–control study, conducted on a large administrative database in the US from 2005 to 2008, and including 1,269 hospitalized cases with acute pancreatitis, showed that treatment with incretin-based therapy (sitagliptin and exenatide) is associated with a doubled risk of developing acute pancreatitis in comparison with nonusers.Citation69

A previous study has examined the FDA adverse event reporting system (AERS) database, and has noted a 6-fold risk for pancreatitis with the use of sitagliptin or exenatide as compared with other therapies. Moreover, this analysis showed the reported event rate for pancreatic cancer was 2.9-fold greater in patients treated with sitagliptin and exenatide compared with other therapies. Unlike patients treated with GLP-1 agonists (in particular liraglutide), the reported event rate for thyroid cancer did not reach statistical significance in sitagliptin-treated patients. These observations have been explained as being due to incomplete data and reporting bias in the FDA database.Citation70 In preclinical toxicology studies, GLP-1 activation promoted the development of C-cell hyperplasia and medullary thyroid cancer, while this action on human C-cells is uncertain.Citation71 In addition, there is evidence in animal models that DPP-4 inhibition is related to melanoma, prostate cancer, ovarian cancer neuroblastoma, and lung cancer. In malignancy, low levels of DPP-4 seems to be associated with dissemination or metastasis.Citation72 Immunomodulatory effects of DPP-4 inhibition might explain the increased risk for all cancers.Citation72 Examination of pancreata from age-matched organ donors with type 2 diabetes (DM) treated by incretin therapy resulted in a marked expansion of the exocrine and endocrine pancreatic compartments, with increased proliferation and dysplasia, and α-cell hyperplasia.Citation73 Therefore, careful long-term surveillance on the safety profile of DPP-4 inhibitors is mandatory.Citation74

Diabetic patients are at increased risk of CV disease. Rosiglitazone was been withdrawn from the market in the European Union (EU) in 2010,Citation75 because of a possible increased risk of ischemic heart disease associated with its use.Citation76 Several preclinicalCitation77 and clinical studies have suggested a possible beneficial effect on CV risk associated with DPP-4 inhibitors, which also seem to possess a direct effect on the heart, independent of the incretin system.Citation78 They may exert some favorable effects on risk factors, resulting in a reduction of blood pressure, an improvement of postprandial lipid levels, and a reduction of high-sensitivity C-reactive protein (hsCRP).Citation25,Citation78 The endothelial dysfunction is also improved by gliptins.Citation79 Several large randomized Phase III trials are ongoing and will increase our knowledge about the effect on CV outcomes and safety.Citation80Citation83

Focus on alogliptin

Overall, the tolerability profile of alogliptin, used alone or in association with other antidiabetic agents, did not differ from that of placebo. Severe hypoglycemia has never been reported; however, skin-related adverse events (especially pruritus) were more common in patients treated with alogliptin compared with other treatment groups.Citation84,Citation85 Although in preclinical studies, the use of other DPP-4 inhibitors, such as saxagliptin and vildagliptin, have been associated with necrotic skin lesions in monkeys,Citation84Citation86 these events have not been observed in clinical trials. In the postmarketing phase, some patients treated with sitagliptin presented Stevens–Johnson syndrome and other exfoliative skin reactions, besides serious allergic reactions and anaphylaxis.Citation87

The combination of alogliptin and metformin is well tolerated. Nasopharyngitis was the most commonly reported adverse event in one study,Citation48 and the overall incidence of infections was highest among the other adverse events. Alogliptin is also safe when added to pioglitazone in metformin-treated patients. The incidence of skin events was similar among treatment groups, while the incidence of infections was slightly greater in patients treated with alogliptin 25 mg plus pioglitazone than pioglitazone alone or with alogliptin 12.5 mg.Citation47 Kaku et alCitation46 observed that nasopharyngitis, even if of mild severity, was the most commonly reported adverse event when alogliptin was added to pioglitazone in naïve patients. The combination of alogliptin (25 mg) and pioglitazone induced edema–related events (incidence ≥3%), which were not observed with a lower dosage of alogliptin.Citation46 The safety profile of the combination alogliptin and sulfonylurea is also favorable, without an increased incidence of hypoglycemia, as compared with placebo.Citation41 Finally, alogliptin added to insulin also shows an acceptable tolerability profile, characterized by gastrointestinal, skin, and infection-related events, without increasing weight gain and the incidence of hypoglycemia.Citation43 The frequency of hypoglycemia with alogliptin reported in is that obtained from four studies;Citation38Citation41 in two of these studies,Citation40,Citation41 alogliptin was added to a previous sulfonylurea treatment, which was associated with higher prevalence of hypoglycemia, which is not different from placebo. The analysis of data from shows that the overall frequency of hypoglycemia is 3.57 (mean, where SD: 4.76) or 1.0 (median, where interquartile range: 1.0–4.6).

No clinically meaningful changes in laboratory test results have been reported.Citation39,Citation43,Citation46 Moreover, few patients died, but the fatal events were not considered to be related to study medication.Citation39,Citation46,Citation47 In the study of Nauck et al,Citation39 two patients in the alogliptin (25 mg) + metformin group reported severe pulmonary embolism and congestive heart failure, which were considered ‘possibly related’ to the study drug. On the other hand, alogliptin seems to have anti-atherosclerotic effects, including decreasing cholesterol and low density lipoproteins,Citation88 both alone and in association with pioglitazone, with a potential reduction of CV risk in patients with type 2 diabetes.Citation55,Citation88 Moreover, a pool analysis of six studies showed that the tolerability of alogliptin was similar in younger and elderly patients.Citation44

Patient-focused perspectives

Unlike incretin mimetics, which need subcutaneous injections, DPP-4 inhibitors are administrated by oral ingestion. The different route of administration could influence patients’ compliance, leading to possible increased adherence to therapy in patients treated with DPP-4 inhibitors. However, some evidence suggests higher patient satisfaction with GLP-1 analogs than gliptins.Citation89,Citation90 A review on patient-reported outcomes of incretin-based therapies showed that patients’ satisfaction when treated with GLP-1 receptor agonists was greater in comparison with DPP-4 inhibitors, probably due to greater efficacy and weight loss.Citation90 Patients’ perception of hypoglycemic condition was similar between the two groups. In a study comparing exenatide and sitagliptin, both groups experienced significant improvements on psychological well-being, although exenatide improved patients’ satisfaction more than sitagliptin.Citation91 Moreover, weight-related quality of life also improved in patients treated with incretin-based therapies.Citation90 Overall, patients were highly satisfied with an incretin-based treatment compared with traditional antidiabetic treatments.

Place in therapy

The recent Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes states that metformin, if not contraindicated and if tolerated, is the preferred and most cost-effective first agent.Citation4 If metformin cannot be used, another oral agent could be chosen, such as a sulfonylurea/glinide, pioglitazone, or a DPP-4 inhibitor. With a distinct paucity of long-term comparative-effectiveness trials available, uniform recommendations on the best agent to be combined with metformin cannot be made.Citation11 Thus, the advantages and disadvantages of specific drugs for each patient should be considered.

The DPP-4 inhibitors represent a highly promising, novel class of oral agents for the treatment of type 2 diabetes. Their novelty lies in their dual action on α- and β-cell function, leading to an improved profile of glucagon and insulin secretion patterns after meal. These drugs are weight-neutral, do not provoke hypoglycemia, and are not associated with gastrointestinal adverse events. Long-term clinical trial data are not yet available to assess the sustainability of glycemic control and protection of β-cell mass. The interference of the DPP-4 inhibitors with immune function is poorly understood and warrants further research. Another potential disadvantage is a higher cost per day of clinical use as compared to insulin, metformin, or pioglitazone, which is an economic drawback for the DPP-4 inhibitors.Citation92

Like other DPP-4 inhibitors, alogliptin is a novel, and hence, costly agent of modest to moderate efficacy. Even then, the DPP-4 inhibitors have found a place in the treatment of vulnerable elderly patients because of minimal risk of hypoglycemia and lack of significant drug–drug interactions. Its primary use will presumably be as an adjunct to other hypoglycemic agents rather than as a first-line agent, although its primary use can be foreseen for patients who are metformin intolerant or in those with renal insufficiency where metformin is contraindicated. Alogliptin will be used most in patients in whom it is especially important to avoid hypoglycemic events: in patients with congestive heart failure, renal failure, and liver disease, hypoglycemia can be more severe and refractory to treatment. In the elderly, hypoglycemic events increase the risk of injurious falls as well as coronary events. Alogliptin and other DPP-4 inhibitors could potentially replace the sulfonylureas in such vulnerable patients. Moreover, due to the paucity of head-to-head clinical data between DDP-4 inhibitors,Citation93 indirect comparisons assessing their efficacy or safety do not allow us to establish if one agent is superior to another within the class. Longer duration studies with careful post-approval surveillance are needed to assess the safety of alogliptin. Such large-scale, long-duration studies not only will characterize the long-term safety of alogliptin but should also shed light on possible β-cell preservation.

Disclosure

The authors report no conflicts of interest in this work.

References

  • Whiting DR Guariguata L Weil C Shaw J IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030 Diabetes Res Clin Pract 2011 94 3 311 321 22079683
  • Go AS Mozaffarian D Roger VL American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics – 2013 update: a report from the American Heart Association Circulation 2013 127 1 e6 e245 Page 13 23239837
  • American Diabetes Association Position Statement. Standards of medical care in diabetes – 2013 Diabetes Care 2013 36 Suppl 1 S11 S66 23264422
  • Inzucchi SE Bergenstal RM Buse JB American Diabetes Association (ADA) European Association for the Study of Diabetes (EASD) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2012 35 6 1364 1379 22517736
  • Selvin E Bolen S Yeh HC Cardiovascular outcomes in trials of oral diabetes medications Arch Intern Med 2008 168 19 2070 2080 18955635
  • Esposito K Bellastella G Giugliano D When metformin fails in type 2 diabetes mellitus Arch Intern Med 2011 171 4 365 366 21357815
  • Giugliano D Ceriello A Esposito K HbA1c targets for type 2 diabetes: How many, …how far! Diabetes Res Clin Pract 2012 96 3 414 415 21963106
  • Colagiuri S Optimal management of type 2 diabetes: the evidence Diabetes Obes Metab 2012 14 Suppl 1 3 8 22118704
  • Esposito K Chiodini P Capuano A Petrizzo M Improta MR Giugliano D Basal supplementation of insulin lispro protamine suspension versus insulin glargine and detemir for type 2 diabetes: meta-analysis of randomized controlled trials Diabetes Care 2012 35 12 2698 2705 23173139
  • Giugliano D Esposito K Clinical inertia as a clinical safeguard JAMA 2011 305 15 1591 1592 21505139
  • Esposito K Ceriello A Giugliano D Does personalized diabetology overcome clinical uncertainty and therapeutic inertia in type 2 diabetes? EndocrineEpub Accessed March 12, 2013
  • Gutniak M Ørskov C Holst JJ Ahrén B Efendic S Antidiabetic effect of glucagon-like peptide-1 (7–36) amide in normal subjects and patients with diabetes mellitus N Engl J Med 1992 326 20 1316 1322 1348845
  • Elrick H Stimmler L Hlad CJJr Arai Y Plasma insulin response to oral and intravenous glucose administration J Clin Endocrinol Metab 1964 24 10 1076 1082 14228531
  • Creutzfeldt W The incretin concept today Diabetologia 1979 16 2 75 85 32119
  • Baggio LL Drucker DJ Biology of incretins: GLP-1 and GIP Gastroenterology 2007 132 6 2131 2157 17498508
  • Doyle ME Egan JM Mechanisms of action of glucagon-like peptide 1 in the pancreas Pharmacol Ther 2007 113 3 549 593
  • Drucker DJ Nauck MA The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 2006 368 9548 1696 1705 17098089
  • Nauck MA Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications Am J Med 2011 124 Suppl 1 S3 S18 21194578
  • Baetta R Corsini A Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences Drugs 2011 71 11 1441 1467 21812507
  • Dhillon S Sitagliptin: a review of its use in the management of type 2 diabetes mellitus Drugs 2010 70 4 489 512 20205490
  • Keating GM Vildagliptin: a review of its use in type 2 diabetes mellitus Drugs 2010 70 16 2089 2112 20964454
  • Neumiller JJ Campbell RK Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus Am J Health Syst Pharm 2010 67 18 1515 1525 20811029
  • Scott LJ Alogliptin: a review of its use in the management of type 2 diabetes mellitus Drugs 2010 70 15 2051 2072 20883057
  • Scott LJ Linagliptin: in type 2 diabetes mellitus Drugs 2011 71 5 611 624 21443284
  • Scheen AJ A review of gliptins in 2011 Expert Opin Pharmacother 2012 13 1 81 99 22149369
  • Verspohl EJ Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors Pharmacol Ther 2009 124 1 113 138 19545590
  • Thomas L Eckhardt M Langkopf E Tadayyon M Himmelsbach F Mark M (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylm ethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors J Pharmacol Exp Ther 2008 325 1 175 182 18223196
  • Gallwitz B Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes Diabetes Metab Syndr Obes 2013 6 1 9 23319869
  • Gupta V Kalra S Choosing a gliptin Indian J Endocrinol Metab 2011 15 4 298 308 22029001
  • Golightly LK Drayna CC McDermott MT Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors Clin Pharmacokinet 2012 51 8 501 514 22686547 Erratum in Clin Pharmacokinet 2012 51 12 831
  • Richard KR Shelburne JS Kirk JK Tolerability of dipeptidyl peptidase-4 inhibitors: a review Clin Ther 2011 33 11 1609 1629 22071236
  • Scheen AJ Pharmacokinetics of dipeptidylpeptidase-4 inhibitors Diabetes Obes Metab 2010 12 8 648 658 20590741
  • Kania DS Gonzalvo JD Weber ZA Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus Clin Ther 2011 33 8 1005 1022 21802144
  • Brown DX Evans M Choosing between GLP-1 receptor agonists and DPP-4 inhibitors: a pharmacological perspective J Nutr Metab 2012 2012 381713 23125920
  • Scheen AJ Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug–drug interactions Clin Pharmacokinet 2010 49 9 573 588 20690781
  • Esposito K Cozzolino D Bellastella G Dipeptidyl pepti-dase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials Diabetes Obes Metab 2011 13 7 594 603 21320267
  • Scheen AJ Charpentier G Ostgren CJ Hellqvist A Gause-Nilsson I Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus Diabetes Metab Res Rev 2010 26 7 540 549 20824678
  • DeFronzo RA Fleck PR Wilson CA Mekki Q Alogliptin Study 010 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study Diabetes Care 2008 31 12 2315 2317 18809631
  • Nauck MA Ellis GC Fleck PR Wilson CA Mekki Q Alogliptin Study 008 Group Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study Int J Clin Pract 2009 63 1 46 55 19125992
  • Pratley RE Reusch JE Fleck PR Wilson CA Mekki Q Alogliptin Study 009 Group Efficacy and safety of the dipeptidyl pepti-dase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study Curr Med Res Opin 2009 25 10 2361 2371 19650752
  • Pratley RE Kipnes MS Fleck PR Wilson C Mekki Q Alogliptin Study 007 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy Diabetes Obes Metab 2009 11 2 167 176 19125778
  • Seino Y Fujita T Hiroi S Hirayama M Kaku K Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension Curr Med Res Opin 2011 27 Suppl 3 21 29 22106975
  • Rosenstock J Rendell MS Gross JL Fleck PR Wilson CA Mekki Q Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia Diabetes Obes Metab 2009 11 12 1145 1152 19758359
  • Pratley RE McCall T Fleck PR Wilson CA Mekki Q Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies J Am Geriatr Soc 2009 57 11 2011 2019 19793357
  • Seino Y Fujita T Hiroi S Hirayama M Kaku K Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study Curr Med Res Opin 2011 27 9 1781 1792 21806314
  • Kaku K Itayasu T Hiroi S Hirayama M Seino Y Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study Diabetes Obes Metab 2011 13 11 1028 1035 21682833
  • DeFronzo RA Burant CF Fleck P Wilson C Mekki Q Pratley RE Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes J Clin Endocrinol Metab 2012 97 5 1615 1622 22419732
  • Seino Y Miyata Y Hiroi S Hirayama M Kaku K Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study Diabetes Obes Metab 2012 14 10 927 936 22583697
  • Rosenstock J Inzucchi SE Seufert J Fleck PR Wilson GA Mekki Q Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes Diabetes Care 2010 33 11 2406 2408 20724648
  • Bosi E Ellis GC Wilson CA Fleck PR Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, doubleblind, active-controlled, parallel-group study Diabetes Obes Metab 2011 13 12 1088 1096 21733058
  • Kutoh E Ukai Y Alogliptin as an initial therapy in patients with newly diagnosed, drug naıve type 2 diabetes: a randomized, control trial Endocrine 2012 41 3 435 441 22249941
  • Goldfine AB Assessing the cardiovascular safety of diabetes therapies N Engl J Med 2008 359 11 1092 1095 18784098
  • US Food Drug Administration FDA announces new recommendations on evaluating cardiovascular risk in drugs intended to treat type 2 diabetes [press release] Silver Springs, MD US Food and Drug Administration 2008 12 17 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116994.htm Accessed April 29, 2013
  • White WB Pratley R Fleck P Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus Diabetes Obes Metab 2013 15 7 668 673 23489301
  • White WB Bakris GL Bergenstal RM EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome Am Heart J 2011 162 4 620 626 e1 21982652
  • Neumiller JJ Wood L Campbell RK Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus Pharmacotherapy 2010 30 5 463 484 20411998
  • Karagiannis T Paschos P Paletas K Matthews DR Tsapas A Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis BMJ 2012 344 e1369 22411919
  • Mikhail N Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes Curr Drug Saf 2011 6 5 304 309 22424537
  • Amori RE Lau J Pittas AG Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis JAMA 2007 298 2 194 206 17622601
  • Monami M Ahrén B Dicembrini I Mannucci E Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials Diabetes Obes Metab 2013 15 2 112 120 22925682
  • Gooßen K Gräber S Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis Diabetes Obes Metab 2012 14 12 1061 1072
  • Desai S Brinker A Swann J Iyasu S Sitagliptin-associated drug allergy: review of spontaneous adverse event reports Arch Intern Med 2010 170 13 1169 1171 20625027
  • Willemen MJ Mantel-Teeuwisse AK Straus SM Meyboom RH Egberts TC Leufkens HG Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase Diabetes Care 2011 34 2 369 374 21270195
  • Noel RA Braun DK Patterson RE Bloomgren GL Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study Diabetes Care 2009 32 5 834 838 19208917
  • US Food Drug Administration Information for Healthcare Professionals – Acute pancreatitis and sitagliptin (marketed as Januvia and Janumet) Silver Spring, MD US Food and Drug Administration 9 25 2009 Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProvid-ers/DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm Accessed March 19, 2013
  • US Food Drug Administration Byetta (exenatide); Audience: Endocrinologists, other healthcare professionals, consumers Silver Spring, MD US Food and Drug Administration [updated June 16, 2009; cited May 30, 2011]. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm079781.htm Accessed June 18, 2013
  • US Food Drug Administration FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes Silver Spring, MD US Food and Drug Administration [March 14, 2013; updated March 18, 2013]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm343187.htm Accessed June 18, 2013
  • Singh S Chang HY Richards TM Weiner JP Clark JM Segal JB Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: A population-based matched case-control study JAMA Intern Med 2013 173 7 534 539 23440284
  • Elashoff M Matveyenko AV Gier B Elashoff R Butler PC Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies Gastroenterology 2011 141 1 150 156 21334333
  • Drucker DJ Sherman SI Gorelick FS Bergenstal RM Sherwin RS Buse JB Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits Diabetes Care 2010 33 2 428 433 20103558
  • Garg MK Kharb S Pandit A Prescribing gliptins: enthusiasm should be coupled with caution Indian J Endocrinol Metab 2012 16 2 324 325 22470884
  • European Medicines Agency (EMA) EMA recommends suspension of Avandia, Avandamet and Avaglim [press release] London, UK European Medicines Agency [cited May 30, 2011]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/09/WC500096996.pdf Accessed June 18, 2013
  • Butler AE Campbell-Thompson M Gurlo T Dawson DW Atkinson M Butler PC Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors DiabetesEpub 3 22 2013
  • Kahn SE Incretin therapy and islet pathology – A time for caution DiabetesEpub 4 17 2013
  • Nissen SE Wolski K Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 2007 356 24 2457 2471 17517853
  • Bose AK Mocanu MM Carr RD Brand CL Yellon DM Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury Diabetes 2005 54 1 146 151 15616022
  • Jose T Inzucchi SE Cardiovascular effects of the DPP-4 inhibitors Diab Vasc Dis Res 2012 9 2 109 116 22337893
  • Fadini GP Boscaro E Albiero M The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha Diabetes Care 2010 33 7 1607 1609 20357375
  • Merck TECOS: Sitagliptin Cardiovascular Outcome Study ClinicalTrialsgov [website on the Internet] Bethesda, MD US National Library of Medicine 2008 [updated August 14, 2012]. Available from: http://clinicaltrials.gov/show/NCT00790205. NLM identifier: NCT00790205Accessed June 18, 2013
  • Takeda EXAMINE: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome ClinicalTrialsgov [website on the Internet] Bethesda, MD US National Library of Medicine 2009 [updated June 11, 2013]. Available from: http://clinicaltrials.gov/show/NCT00968708. NLM identifier: NCT00968708Accessed June 18, 2013
  • AstraZeneca SAVOR-TIMI 53: Does Saxagliptin Reduce the Risk of Cardiovascular Events when Used Alone or Added to Other Diabetes Medications? ClinicalTrialsgov [website on the Internet] Bethesda, MD US National Library of Medicine 2010 [updated November 19, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01107886. NLM identifier: NCT01107886Accessed June 18, 2013
  • Boehringer Ingelheim Pharmaceuticals CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients with Type 2 Diabetes ClinicalTrialsgov [website on the Internet] Bethesda, MD US National Library of Medicine 2010 [updated June 12, 2013]. Available from: http://clinicaltrials.gov/show/NCT01243424. NLM identifier: NCT01243424Accessed June 18, 2013
  • Rendell M Drincic A Andukuri R Alogliptin benzoate for the treatment of type 2 diabetes Expert Opin Pharmacother 2012 13 4 553 563 22296609
  • Andukuri R Drincic A Rendell M Alogliptin: a new addition to the class of DPP-4 inhibitors Diabetes Metab Syndr Obes 2009 2 117 126 21437125
  • European Medicine Agency Summary of Product Characteristics of Vildagliptin London European Medicine Agency Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000771/WC500020327.pdf Accessed June 18, 2013
  • US Food Drug Administration Janumet (sitagliptin/metformin HCl) Tablets Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – January 2008 Silver Spring, MD US Food and Drug Administration [January 2008; updated June 19, 2009]. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm106669.htm Accessed June 18, 2013
  • Kapoor S Potent antiatherosclerotic effects of alogliptin in addition to its potent antidiabetic effects Diabetes Metab Syndr Obes 2012 5 121 123 22654521
  • Eliasson B Möller-Goede D Eeg-Olofsson K Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study Diabetologia 2012 55 4 915 925 22237690
  • Russell S Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction Int J Clin Pharm 2013 35 2 159 172 23263796
  • Davies M Speight J Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus Diabetes Obes Metab 2012 14 10 882 892 22420869
  • Best JH Rubin RR Peyrot M Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment Diabetes Care 2011 34 2 314 319 21270189
  • Irons BK Weis JM Stapleton MR Edwards KL An update in incretin-based therapy: a focus on dipeptidyl peptidase – 4 inhibitors Curr Diabetes Rev 2012 8 3 169 182 22429011
  • Scheen AJ Charpentier G Ostgren CJ Hellqvist A Gause-Nilsson I Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus Diabetes Metab Res Rev 2010 26 540 549 20824678